Preliminary study on the cooperation of IL-6 and mB7-1 in the induction of effective antitumor immunityin vitro

Abstract

To find a new way for gene therapy against tumors with weak immunogenicity, the effect of mB7-1 costimulation alone, or combined with IL-6, in inducing antitumor immunityin vitro was investigated. It was found that mB7-1 cD-NA transfected B16 cells (B16-mB7-1) induced the expansion of effector lymphocytes and the generation of specific lytic activity more effectively than wild type B16 melanoma cells (B16-wt) or mock-transfected B16 cells (B16-neo) did. (P < 0. 01), IL-6 could effectively stimulate lymphocytes proliferation, but failed to enhance its cytotoxicity, while the combination of mB7-1 and IL-6 increased both lymphocyte proliferative response and T-cell-mediated cytotoxicity more significantly than B7-1 or IL-6 did alone (P<0. 01). It was inferred that the costimulatory molecule B7-1 is required for the activation and proliferation of T lymphocytes; the expression of mB7-1 in tumor cells could increase their immunogenicity and induce effective antitumor immune response, and the combination of B7-1 and IL-6 could induce more effective antitumor immunity, indicating that cooperation of IL-6 and mB7-1 plays a role in T lymphocyte activation.

Keywords

B7-1 (CD80) / interleukin-6 / B16 melanoma / tumor /gene therapy

References

[1] TravisJ. A Stimulating new approach to cancer treatment. Science, 1993, 259310-310

[2] ChenL, AsheS M, BradyW A, et al. . Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 1992, 711093-1093

[3] JonathanH E, BurdenM N, VinogradorDV, et al. . Interactions of CD80 and CD86 with CD28 and CTLA-4. J Immunol, 1996, 562700-2700

[4] ChenL, MoryY, ZilbersteinA, et al. . Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-beta 2. Proc Natl Acad Sci USA, 1988, 858037-8037

[5] SunW H, KreisleR A, PhillipsA W, et al. . In vivo andin vitro characteristics of interleukin 6 transfected B16 melanoma cells. Cancer Res, 1992, 525412-5412

[6] QuS, LiuR Y, WangJ B, et al. . Experimental study on the antitumor effect of mouse B7-1. J Tongji Med Uni, 1999, 19(1): 10-10

[7] LDH 1989,9(4):218

[8] SchwartzR H. A cell culture model for T lymphocyte clonal anergy. Science, 1990, 2481349-1349

[9] TownsendS E, AllisonJ P. Tumor rejection after direct costimulation of CD8⁺ T cells by B7-1 transfected melanoma cells. Science, 1993, 259368-368

[10] ChenL, McGowanP, AsheS, et al. . Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med, 1994, 179523-523

[11] LiY, HellstromK E, NewbySA, et al. . Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumor. J Exp Med, 1996, 183639-639

[12] CavalloF, Martin-FontechaA, BelloneM, et al. . Coexpression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur J Immunol, 1995, 251154-1154

[13] LuL, ShenR N, BroxmeyerH E. In vivo effects of recombinant human interleukin-6, alone or in combination with local Irradiation, on tumor growth in Lewis lung carcinoma-bearing mice. Int J Cell Cloning, 1991, 9511-511

[14] MuleJ J, McIntoshJ K, JablonD M, et al. . Antitumor activity of recombinant interleukin-6 in mice. J Exp Med, 1990, 171629-629

[15] SeventerG A, NewmanW, ShimizuY, et al. . Analysis of T cell stimulation by superantigen plus major histocompatibility complex class I molecules or by CD3 monocolonal antibody: costimulation by purified adhesion ligands VCAM-1, ICAM-1, but not ELAM-1. J Exp Med, 1991, 174901-901

[16] BaskarS, ClementsV K, GlimcherL H, et al. . Rejection of MHC class I transfected Tumor cells requires induction of tumor-encoded B7-1 and (or) B7-2 costimulatory molecules. J Immunol, 1996, 1563821-3821

[17] ZitvogelL, RobbinsP D, StorkusW J, et al. . Interleukin-12 and B7-1 costimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol, 1996, 261335-1335